PCRX Q3 2025 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$180M+6.5% YoY

Gross Profit

$145M80.9% margin

Operating Income

$6M3.5% margin

Net Income

$5M3.0% margin

EPS (Diluted)

$0.12

QoQ Revenue Growth

-0.9%

Cash Flow

Operating Cash Flow

$61M

Free Cash Flow

$57M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$570M

Stockholders' Equity

$727M

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$180M	$169M	+6.5%
Gross Profit	$145M	$130M	+12.0%
Operating Income	$6M	-$140M	+104.6%
Net Income	$5M	-$143M	+103.8%

Revenue Segments

Product

$178M51%

EXPAREL

$140M40%

ZILRETTA

$29M8%

Bupivacaine Liposome Injectable Suspension

$3M1%